E arly ST within 30 days after primary percutaneous coronary intervention (PCI) in patients with ST-segmentelevation myocardial infarction (STEMI) is a serious complication, resulting in increased mortality. 1-4 Three of 4 randomized trials have demonstrated an increased risk of acute (≤24 hours) ST with bivalirudin compared with heparin with either routine or provisional glycoprotein IIb/IIIa receptor inhibitor (GPI) use after primary PCI in Background-Early stent thrombosis (ST) within 30 days after primary percutaneous coronary intervention in ST-segmentelevation myocardial infarction is a serious event. We sought to determine the predictors of and risk of mortality after early ST according to procedural antithrombotic therapy.
Stent Thrombosis and Mortality After Primary PCI STEMI, with no significant difference in the rates of subacute (1-30 days) ST. [1] [2] [3] [4] In the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and in a patient-level pooled analysis from HORIZONS-AMI and European Ambulance Acute Coronary Syndrome Angiography (EUROMAX) trials, despite a greater risk of acute and early ST with bivalirudin compared with heparin±GPI, cardiac mortality within 30 days was consistently reduced with bivalirudin. 3, 5 In addition, this pooled analysis from the HORIZONS and EUROMAX trials 5 indicated a differential mortality risk after acute ST depending on antithrombotic regimen. In this context, the extent to which the increased propensity for early ST associated with bivalirudin translates into adverse outcomes compared with heparin±GPI has not been examined in detail. We therefore sought to determine the independent predictors of acute, subacute, and early ST and to evaluate whether the risk of mortality differed according to antithrombotic therapy use in patients who develop acute, subacute, and early ST after primary PCI in the HORIZONS-AMI and EUROMAX trials.
Methods

Patient Population
This study was drawn from a prespecified pooled analysis of patientlevel data from the HORIZONS-AMI and EUROMAX trials. 2, 3 As previously described, 2, 3, 5 both trials were international, randomized, open-label studies, randomizing patients with STEMI undergoing primary PCI 1:1 to bivalirudin or heparin with either routine of provisional GPI use. In brief, HORIZONS-AMI enrolled 3602 patients between March 2005 and May 2007 from 123 centers in 11 countries, among whom 3202 had a stent implanted. EUROMAX enrolled 2198 patients between March 2010 and June 2013 from 65 European sites, among whom 1733 had a stent implanted. Each study was approved by an institutional review committee at each participating center and all subjects gave written informed consent. The present pooled study population is thus comprised of 4935 STEMI patients at risk for ST after primary PCI, including 2479 and 2456 patients who were randomized to bivalirudin and heparin±GPI, respectively. The baseline clinical and angiographic characteristics of patients randomized to the 2 treatment groups were well matched (Tables I and II in the Data  Supplement) .
Treatments
Randomization and study drugs were initiated at the tertiary hospital in HORIZONS-AMI and in the transporting ambulance in EUROMAX. In both trials, patients assigned to bivalirudin received a bolus of 0.75 mg/kg, followed by an infusion of 1.75 mg/kg per hour during the PCI procedure (adjusted for renal insufficiency). In HORIZONS-AMI, the infusion was terminated immediately after successful PCI, but could be continued in case of suboptimal results after PCI. The EUROMAX protocol specified that the infusion could be routinely continued for ≤4 hours at 0.25 or 1.75 mg/kg per hour, at the investigator's discretion. Bailout GPI use was allowed in both trials for refractory thrombotic complications during PCI.
Patients in the control arm of HORIZONS-AMI received an intravenous heparin bolus of 60 IU/kg, with subsequent boluses targeted to an activated clotting time of 200 to 250 s, and routine use of a GPI (either abciximab or double-bolus eptifibatide). In the EUROMAX trial, patients assigned to the heparin group received either unfractionated heparin (recommended doses of 100 IU/kg without a GPI or 60 IU/ kg with a GPI) or an intravenous bolus of enoxaparin (0.5 mg/kg). GPI use was left to physician preference and was categorized as either routine (started before PCI) or provisional (bailout) for refractory thrombotic complications. GPI were administered at the approved doses and regimens-abciximab or eptifibatide in HORIZONS-AMI, and abciximab, eptifibatide or tirofiban in EUROMAX. In both trials, patients received aspirin and a loading dose of an oral platelet P2Y12 receptor antagonist (clopidogrel only in HORIZONS-AMI, and clopidogrel, prasugrel, or ticagrelor in EUROMAX) as early as possible after first medical contact. Dual antiplatelet therapy was continued for at least 1 year in both studies. Both trials were powered for 30-day primary end points. At the present time, follow-up is complete to 3 years in HORIZONS-AMI and 30 days in EUROMAX. For the present analysis, we therefore considered outcomes through 30 days.
End Points and Statistics
The end points of interest in the present trial were 30-day all-cause mortality and ST (acute, subacute, and early). ST was defined according to the definite or probable Academic Research Consortium criteria. 6 All acute ST events occurred after the primary PCI procedure had been completed. Events in both trials were adjudicated by an independent committee blinded to randomization allocation.
Continuous variables are presented as mean (±SD) and were compared by ANOVA. Categorical variables are presented as counts and percentages and were analyzed with the Cochran-Mantel-Haenszel test controlling for study. ST and mortality rates were also calculated by Kaplan-Meier methodology and compared with log-rank tests. Predictors of 30-day ST were determined by multivariable logistic regression. Models were built in a stepwise, backwards and forwards fashion, with significance levels of 0.15 and 0.10 required to allow a variable to enter and stay in the model. The following covariates were considered: age >65 years, sex, bivalirudin versus heparin±GPI, clopidogrel versus ticagrelor/prasugrel loading dose, calculated baseline creatinine clearance ≤60 mL/min, diabetes mellitus, previous PCI, stent type, Killip class II-IV, preprocedural thrombolysis in myocardial infarction (TIMI) flow 0/1, and postprocedural TIMI flow 0/1. Heterogeneity between trials was examined with the Breslow-Day test. Among patients with early ST, the propensity-adjusted risk of subsequent mortality within 30 days was determined for patients treated with bivalirudin versus heparin±GPI in a Cox multivariable model, with ST treated as a time-dependent variable; all differing baseline covariates were included in the propensity model. Among variables included in the propensity score were aged >65 years, sex, clopidogrel versus ticagrelor/prasugrel loading dose, calculated
WHAT IS KNOWN
• Early ST within 30 days after primary PCI is a serious complication, resulting in increased mortality.
• Three of 4 randomized trials have demonstrated an increased risk of acute (≤24 hours) ST with bivalirudin compared with heparin with either routine or provisional GPI use after primary PCI, with no significant difference in the rates of subacute (1-30 days) ST.
WHAT THE STUDY ADDS
• The increased hazard of ST in bivalirudin-treated patients was confined to the first 4 hours after PCI; thereafter the rates of ST were similar with bivalirudin and heparin±GPI through 30-day follow-up.
• Although more patients developed early ST after bivalirudin compared with heparin±GPI, 30-day mortality was considerably less frequent when early ST occurred in bivalirudin-treated patients. As a result, fewer patients treated with bivalirudin compared with heparin±GPI died within 30 days because of ST. baseline creatinine clearance ≤60 mL/min, diabetes mellitus, previous PCI, stent type, Killip class II-IV, preprocedural TIMI flow 0/1, postprocedural TIMI flow 0/1, anemia, platelet count, current smoker, access site, hyperlipidemia, hypertension, previous coronary artery bypass graft, single-vessel disease, and previous myocardial infarction. All analyses are performed on the intention-to-treat population excluding the patients who did not receive a stent and a 2-sided P value of <0.05 was considered statistically significant. All analyses were performed with SAS statistical software (SAS Institute Inc, Cary, NC).
Results
Incidence of ST and Subsequent Mortality
Early ST developed in 100 (2.0%) of 4935 STEMI patients with stents implanted during primary PCI, including 85 (85.0%) definite and 15 (15.0%) probable ST events. Within 30 days of study enrollment, 20 patients (20.0%) with early ST died. All deaths within 30 days were adjudicated as cardiac deaths.
Predictors of ST
As shown in Table 1 , patients who developed early ST were more likely to have undergone a previous PCI, less likely to have hyperlipidemia and previous myocardial infarction, presented with greater Killip class at baseline, had higher baseline platelet counts and were more likely to have baseline TIMI flow 0/1 at index angiography.
As shown in Figure 1 , patients randomized to bivalirudin compared with heparin±GPI had a higher rate of early ST (60 versus 40 events, 2.5% versus 1.6%, P=0.04) because of a higher incidence of acute ST (1.5% versus 0.2%, P<0.0001), with similar rates of subacute ST (1.0% versus 1.4%, P=0.24). The higher rate of acute ST with bivalirudin was confined to the first 4 hours after PCI (1.1% versus 0.04%, P<0.0001), whereas there was no significant difference in acute ST rates between 4 and 24 hours with bivalirudin versus heparin±GPI (0.2% versus 0.4%, P=0.28; Figure 2 ). Among patients who developed early ST, those treated with bivalirudin compared with heparin±GPI were younger, had less heart failure (Killip class II-IV), and less baseline anemia, but were more likely to have baseline TIMI 0/1 flow ( Table 2) .
By multivariable analysis, the independent predictors of early ST were baseline TIMI grade flow 0/1 and Killip class ≥2 at presentation (Table 3) . A trend toward increased early ST with bivalirudin was present, which did not reach statistical significance. Randomization to bivalirudin and baseline TIMI flow 0/1 were independently associated with acute ST, whereas only Killip class ≥2 was independently predictive of subacute ST.
Clinical Events After ST
Despite the increased rates of early ST with bivalirudin, 30-day mortality after early ST was significantly less frequent in bivalirudin-treated compared with heparin±GPI-treated patients ( Figure 3 ; Table 4 ). Mortality within 30 days occurred in 4 of 60 (6.7%) bivalirudin-treated patients with early ST compared with 16 of 40 (40.0%) heparin±GPI-treated patients with early ST (relative risk, 0.19; 95% CI, 0.07-0.52; P=0.0002). By propensity-adjusted Cox modeling, treatment with bivalirudin compared with heparin±GPI was an independent predictor for reduced 30-day mortality after early ST (adjusted hazard ratio, 0.12; 95% CI, 0.04-0.39; P=0.0004). The lower mortality in bivalirudin-treated patients was consistent for both acute and subacute ST ( Figure 4 ). Thus, 30-day mortality attributable to early ST occurred in 4 of 2479 (0.2%) bivalirudintreated patients versus 16 of 2456 (0.7%) heparin±GPI-treated patients (P=0.007). Among patients with early ST, there were no significant differences between the 2 treatment groups in the 30-day rates of reinfarction, ischemia-driven revascularization, stroke, or major bleeding (Table 4) .
A list with all deaths related to early ST is provided in Table III in the Data Supplement with listings of important patient characteristics and their propensity scores.
Discussion
In this patient-level pooled analysis from 2 large-scale, multicenter trials in which 4935 patients with STEMI undergoing primary PCI with stent implantation were randomized to anticoagulation with bivalirudin versus heparin±GPI, ST occurring within 30 days was more frequent in bivalirudin-treated patients. This increased hazard was confined to the first 4 hours after PCI; thereafter the rates of ST were similar with bivalirudin and heparin±GPI through 30-day follow-up. However, although more patients developed early ST after bivalirudin compared with heparin±GPI (60 versus 40 events), 30-day mortality was considerably less frequent when early ST occurred in bivalirudin-treated patients. As a result, fewer patients treated with bivalirudin compared with heparin±GPI, respectively, died within 30 days because of ST (4 versus 16 deaths).
Our findings of a higher hyperacute ST hazard confined to the first 4 hours after PCI with bivalirudin compared with heparin±GPI confirms previous observations. [1] [2] [3] The mechanism of this risk is presumably lack of sufficient antithrombin activity in the early hours after stent implantation, before oral antiplatelet agent effectiveness. 7, 8 This risk may be amplified given the fact that bivalirudin possesses inherent antiplatelet activity, blocking both collagen-induced and thrombin-induced platelet activation. 9 The risk of acute ST with immediate postprocedural bivalirudin discontinuation may be reduced with the use of heparin in the emergency room, without increasing bleeding. 10 Prolongation of the post-PCI infusion of bivalirudin at the low 0.25 mg/kg per hour dose does not reduce the risk of acute ST as shown in the EUROMAX trial. 2 However, a recent randomized trial in China and a subgroup analysis from EUROMAX indicated that prolongation of the infusion at the full PCI dose of 1.75 mg/kg per hour seems effective in mitigating the excess risk of acute ST risk. 4, 11 A recent trial in Italy randomized patients with acute coronary syndrome to bivalirudin infusion during the PCI procedure only or to a prolonged infusion regimen at either the low dose of 0.25 mg/kg per hour or the PCI dose of 1.75 mg/kg per hour for at least 4 hours after the end of the procedure. The primary results did not show a difference in the composite outcome of ischemic and bleeding events, including ST, between the long or short infusion arms. However, an exploratory analysis published in the supplemental appendix of this trial revealed that within the prolonged infusion arm the 1.75 mg/kg per hour dose fully mitigated the risk of acute ST, whereas the 0.25 mg/kg per hour dose did not, 12 which is consistent with the findings of the aforementioned trial in China and the subgroup analysis from EUROMAX. 4, 11 Additional independent predictors of early ST were Killip class ≥2 at presentation and baseline TIMI grade flow 0/1, representing subgroups of particular concern, although all patients with STEMI in whom stents are implanted should be considered high-risk for ST.
The central finding of this study is that the increased risk of acute ST with bivalirudin did not translate into greater mortality within 30 days. Conversely, in patients in whom acute or subacute ST occurred, mortality was significantly lower if this event occurred in a patient treated with bivalirudin rather than heparin±GPI (by ≈88% in a multivariable analysis which accounted for differences in age and other comorbidities in patients with ST treated with the 2 regimens). Thus, despite the fact that there were 20 more early ST events with bivalirudin than heparin±GPI (an absolute 0.9% increase in early ST), there were in fact 12 fewer deaths because of early ST with bivalirudin (an absolute 0.5% decrease in mortality). 5 The mechanism of observed difference in mortality when early ST occurs after bivalirudin than after heparin±GPI use in primary PCI requires further study. Among patients with early ST, there were no significant differences between the 2 treatment groups in the 30-day rates of reinfarction, ischemiadriven revascularization, stroke or major bleeding, which might otherwise explain the lower mortality in the bivalirudin arm. These findings are, however, consistent with a recent report demonstrating that the cardiac mortality reduction with bivalirudin compared with heparin±GPI in the HORIZONS-AMI trial was in large part because of thrombocytopenia and other nonhematologic mechanisms. 13 In this study, thrombocytopenia did not vary significantly in patients with and without ST-associated mortality.
Single
Patients who developed early ST after bivalirudin were younger and had less baseline heart failure and anemia than in patients who developed early ST after heparin±GPI, which we adjusted for. Although we cannot exclude the possibility that unmeasured confounders related to the differences in baseline demographics may affect the results, several interesting explanatory mechanisms deserve consideration. In addition to the lack of effective antithrombin and antiplatelet activity early, after bivalirudin discontinuation, genetic polymorphisms 15, 16 In a recent study using optical coherence tomography, patients undergoing PCI and treated with bivalirudin compared with heparin had similar in-stent thrombus volume and length, but less platelet-rich white thrombus. 17 Augmented platelet-leukocyte aggregation in vivo has also been reported from the blood of patients treated with heparin+GPI compared with bivalirudin. 18 These data are furthermore consistent with the greater frequency of immunologically mediated thrombocytopenia with heparin+GPI compared with bivalirudin, 13 which could contribute to platelet clumping and ST that may be refractory to treatment in patients already receiving GPI. Conversely, the platelet-leukocyte depleted red thrombus that may be more frequent with bivalirudin is known to be more susceptible to endogenous or pharmacological fibrinolysis, 19 and thus may be more responsive to repeat PCI with potent P2Y12 inhibitors±bailout GPI with lesser impact on clinical outcomes. Finally, bivalirudin may have additional attributes which possibly contribute to survival in the event of ST. Previous studies have shown direct thrombin inhibitors to reduce inflammation, 20,21 apoptosis, 21, 22 and myocardial infarct size, 20 and thereby potentially improve myocardial function 21 and survival. Infarct size tended to be reduced in bivalirudin-treated patients in the HORIZONS-AMI magnetic resonance substudy, 23 and greater coronary flow reserve was noted in patients treated with bivalirudin compared with heparin+GPI in A Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia Among Anti-Platelet and Anti-Thrombotic Agents-Thrombolysis In Myocardial Infarction-30 (PROTECT-TIMI 30) trial. 24 
Limitations
Despite adjustment for covariates known to be predictive of ST and early mortality after primary PCI, we cannot claim causality about our observation that mortality was lower in bivalirudin-treated compared with heparin GPI-treated patients with early ST. Although the ST and mortality events were adjudicated blinded to treatment and the differences in mortality were statistically robust, unmeasured cofounders may call into question the causal nature of the observed relationships. More definitive conclusions warrant additional study. Most control group patients were treated with heparin+GPI, whether the results would have been similar with heparin alone is unknown. Angiograms of the ST episodes and subsequent assessments of ST-segment resolution, post-PCI biomarkers, left ventricular ejection fraction, and infarct size were not available for the present analysis, and thus we cannot state whether the procedural treatments of early ST episodes were more successful in the bivalirudin group, which might have contributed to their improved prognosis. Finally, follow-up of the present analysis was limited to 30 days (the current duration of follow-up from EUROMAX). However, ST and mortality rates tended to be greater in patients treated with heparin±GPI compared with bivalirudin in the HORIZONS-AMI trial between 30 days and 3 years, 25 and it is thus unlikely that the lower absolute mortality after ST observed with bivalirudin in this study would be reversed with further follow-up.
Conclusions
In the present patient-level pooled analysis from 2 large-scale, randomized, multicenter trials, the risk of ST within 30 days was higher among patients treated with bivalirudin compared with heparin±GPI because of a greater hazard of ST within the first 4 hours after PCI. However, mortality after early ST was substantially less in patients randomized to bivalirudin compared with heparin±GPI, and as a result, among all 4935 randomized patients bivalirudin resulted in fewer deaths within 30 days because of ST.
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